On Tuesday, Novartis raised the prospect of divesting its generic drugs unit Sandoz while revising upwards its revenue estimate for its two best-selling pharmaceuticals. “Novartis has commenced a strategic review of the Sandoz Division. The review will explore all options, ranging… Read More ›